Skip to main content

S. 4152

Referred to Committee

A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

Introduced 5/5/2022•117th Congress•Senate

Latest Action

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

5/5/2022 • Senate

Summary

This bill reauthorizes through FY2027 the Food and Drug Administration's Critical Path Public-Private Partnerships, which support medical product innovation, development, and safety.

Introduced in Senate • 5/5/2022

Enter your district to see how this bill affects your community
-

Topics & Subjects

Policy Area: Health

Congressional Votes (0)

No recorded votes yet

Roll call votes will appear here as the bill moves through Congress

Related Federal Spending

Sponsor & Cosponsors (3)

Party Breakdown

2
Democrats
1
Republicans
0
Independents

Sponsor

S[
Sen. Kelly, Mark [D-AZ]

Democrat • AZ

Sponsored 5/5/2022

Cosponsors (2)

S[
S[
Sen. Sinema, Kyrsten [D-AZ]

D-AZ

Joined 5/5/2022

Bill Journey

Originated in the Senate

Introduced

May 5, 2022

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Committee Review

Floor Debate

Passed Chamber

Other Chamber

President

Enacted into Law

Text Versions (1)

Introduced in Senate5/5/2022

Details

Bill TypeS
Current StatusReferred to Committee
Cosponsors2